Analytical reference standards of three potentially genotoxic impurities of nilotinib (Tasigna) are now available from Acanthus Research: Nilotinib Genotoxic Impurity 1 (CAS No. 641571-11-1), Nilotinib Genotoxic Impurity 2 (CAS No.1157857-29-8), and Nilotinib Genotoxic Impurity 3 (CAS No.915711-42-1). All reference standards are of high purity and are accompanied by Certificate of Analysis. To request the CofA please click here.
Control of genotoxic or potentially genotoxic impurities in pharmaceutical products is mandated by European and North American regulatory agencies.
To read more about potentially genotoxic impurities, please click here.
Nilotinib, marketed by Novartis Pharmaceuticals Corporation under the propriety name Tasigna, is a targeted therapy drug classified as a protein-tyrosine kinase inhibitor. Nilotinib is used for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia that is refractory or intolerant to prior therapy, including imatinib. Nilotinib has many molecular targets including BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11 and ZAK.
Order analytical reference standard of:
Nilotinib Genotoxic Impurity 1; Catalogue No. NIL-15-002
Nilotinib Genotoxic Impurity 2; Catalogue No. NIL-15-003
Nilotinib Genotoxic Impurity 3; Catalogue No. NIL-15-004